Literature DB >> 6420853

Characterisation of stocks of Theileria parva by monoclonal antibody profiles.

T Minami, P R Spooner, A D Irvin, J G Ocama, D A Dobbelaere, T Fujinaga.   

Abstract

Sixteen monoclonal antibodies, raised against macroschizonts of Theileria parva, were tested against 10 different stocks of the parasite. The indirect fluorescent antibody test was used to demonstrate that these antibodies showed different binding affinities to macroschizonts of the various stocks. A profile of antibody binding could thus be prepared for each stock. For a given stock the profile was consistently the same irrespective of culture passage level, host cell background and method of antigen preparation. Monoclonal antibody profiles thus appear to provide a means of characterisation of stocks of T parva in vitro, and preliminary evidence suggests that profiles may be used to differentiate strains. The best source of antigen for testing theilerial stocks was macroschizont infected cells raised in culture, but suitable preparations could also be made from lymph node biopsies of cattle infected with East Coast fever. In a field outbreak of disease it might thus be possible rapidly to characterise the strains of T parva involved and plan immunisation and control measures accordingly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6420853

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  28 in total

1.  Analysis of Theileria parva immunodominant schizont surface antigen by two-dimensional polyacrylamide gel electrophoresis and immunoblotting.

Authors:  C Sugimoto; L M Mutharia; W C Brown; T W Pearson; T T Dolan; P A Conrad
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

2.  Concerted evolution at a multicopy locus in the protozoan parasite Theileria parva: extreme divergence of potential protein-coding sequences.

Authors:  R Bishop; A Musoke; S Morzaria; B Sohanpal; E Gobright
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Bovine cytotoxic T-cell clones specific for cells infected with the protozoan parasite Theileria parva: parasite strain specificity and class I major histocompatibility complex restriction.

Authors:  B M Goddeeris; W I Morrison; A J Teale; A Bensaid; C L Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Comparative analysis of infection and transformation of lymphocytes from African buffalo and Boran cattle with Theileria parva subsp. parva and T. parva subsp. lawrencei.

Authors:  C L Baldwin; M N Malu; S W Kinuthia; P A Conrad; J G Grootenhuis
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

5.  Characterisation of the telomeres at opposite ends of a 3 Mb Theileria parva chromosome.

Authors:  B K Sohanpal; S P Morzaria; E I Gobright; R P Bishop
Journal:  Nucleic Acids Res       Date:  1995-06-11       Impact factor: 16.971

6.  Phenotypic characterization of Theileria parva schizonts by two-dimensional gel electrophoresis.

Authors:  C Sugimoto; P A Conrad; L Mutharia; T T Dolan; W C Brown; B M Goddeeris; T W Pearson
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

Review 7.  Live immunisation against Theileria parva: containing or spreading the disease?

Authors:  Declan J McKeever
Journal:  Trends Parasitol       Date:  2007-10-25

8.  Monoclonal antibodies as diagnostics; an appraisal.

Authors:  M Z Siddiqui
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

9.  Parasite strain specificity of precursor cytotoxic T cells in individual animals correlates with cross-protection in cattle challenged with Theileria parva.

Authors:  E L Taracha; B M Goddeeris; S P Morzaria; W I Morrison
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  Genotypic diversity, a survival strategy for the apicomplexan parasite Theileria parva.

Authors:  F Katzer; D Ngugi; A R Walker; D J McKeever
Journal:  Vet Parasitol       Date:  2009-09-23       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.